1 Berlit P. S1-Leitlinie: Neurologische Manifestationen bei COVID-19: Leitlinie der Deutschen Gesellschaft für Neurologie [S1 guideline: neurological manifestations in COVID-19]. DGNeurologie. 2020;1–21.
2 Bösel J, Berlit P. Neurologische Auswirkungen von COVID-19 [Neurological effects of COVID-19]. DGNeurologie. 2020;1–7.
3 Wenting A, Gruters A, van Os Y, et al. COVID-19 Neurological Manifestations and Underlying Mechanisms: A Scoping Review. Front Psychiatry. 2020;11:860.
4 Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021;268(4):1133–70.
5 Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671–83.
6 Lunn MP, Cornblath DR, Jacobs BC, Querol L, van Doorn PA, Hughes RA, Willison HJ. COVID-19 vaccine and Guillain-Barré syndrome: let’s not leap to associations. Brain. 2021;144(2):357–60.
7 Uncini A, Vallat J, Jacobs BC. Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry. 2020;91:1105–10.
8 Keddie S, Pakpoor J, Mousele C, Pipis M, Machado PM, Foster M, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. 2021;144(2):682–93.
9 Ding X, Jiang H, Hu X, Ren H, Cai H. Guillain-Barré Syndrome and Low Back Pain: Two Cases and Literature Review. Open Med (Wars). 2018;13:503–8.
10 Gorson KC, Ropper AH, Muriello MA, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology. 1996;47(3):813–7.
11 Morgan GW, Barohn RJ, Bazan C 3rd, King RB, Klucznik RP. Nerve root enhancement with MRI in inflammatory demyelinating polyradiculoneuropathy. Neurology. 1993;43(3 Pt 1):618–20.